Evidence map›Paper›PMID 24466143›Full record

ArticlePloS one2014

Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.

Dexiang Zhu, Yunshi Zhong, Ye Wei, Lechi Ye, Qi Lin, Li Ren, Qinghai Ye, Tianshu Liu, Jianmin Xu, Xinyu Qin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Impact of neoadjuvant chemotherapy on short-term outcomes after simple and complex minimally invasive minor hepatectomy for colorectal liver metastases: A propensity-score matched and coarsened exact matched study.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · 2024
    Article
  7. Review
  8. Article
  9. Article
  10. Impact of preoperative chemotherapy on perioperative morbidity in combined resection of colon cancer and liver metastases.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Dexiang ZhuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yunshi ZhongDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Ye WeiDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Lechi YeDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qi LinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Li RenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Qinghai YeDepartment of Liver Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Tianshu LiuDepartment of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Jianmin XuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Xinyu QinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWhether patients with resectable colorectal liver metastases (CRLM) receive survival benefit from neoadjuvant chemotherapy remains controversial.

methodsWe retrospectively analyzed 466 patients with resectable CRLM between 2000 and 2010. Patient characteristics and survival data were recorded.

resultsThe patients were divided into one group with neoadjuvant chemotherapy (group NC, n = 121) and another without (group WN, n = 345). There was no difference in 5-year survival (52% vs. 48%) between the two groups. No significant differences were identified between the two groups in terms of 30-day mortality (1.7% vs. 1.2%) or morbidity (33.9% vs. 25.8%). A primary tumor at stage T4, ≥4 liver metastases, the largest liver metastasis ≥5 cm in diameter, and a serum CEA level ≥5 ng/ml were independent prognostic factors. By assigning one point to each, the patients were divided into a low-risk group (0-2) and a high-risk (3-4). The patients in the low-risk group received no survival benefit from neoadjuvant chemotherapy, whereas those in the high-risk group received survival benefit (5-year survival, 39% vs. 33%, P = 0.028).

conclusionsPreoperative neoadjuvant chemotherapy did not increase mortality or complications. Not all resectable patients, only those with >2 independent risk factors, received survival benefit from neoadjuvant chemotherapy.

Indexed as

AdultAgedAged, 80 and overChemotherapy, AdjuvantColorectal NeoplasmsFemaleHumansLiver NeoplasmsMaleMiddle AgedNeoadjuvant TherapyRetrospective StudiesTreatment Outcome

Identifiers

PMID24466143
PMCPMC3897724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.